Alnylam Pharmaceuticalsvs.BioMarin Pharmaceutical
ALNY vs BMRN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Alnylam Pharmaceuticals is about 2.9× larger than BioMarin Pharmaceutical by market cap; Alnylam Pharmaceuticals trades at the lower P/E (37.2 vs 143.4); year to date, BioMarin Pharmaceutical leads (−7.1% vs −43.6%).
Side by side
| ALNY | BMRN | |
|---|---|---|
| Market cap | $30B | $10.5B |
| Price | $224.53 | $54.89 |
| Today | +0.1% | −0.6% |
| Return YTD | −43.6% | −7.1% |
| Return 1Y | −51.2% | +0.9% |
| Since June 26, 2026 | −22.9% | −7.0% |
| P/E | 37.2 | 143.4 |
| P/S | 6.3 | 3.1 |
| P/B | 22.2 | 1.7 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Alnylam PharmaceuticalsALNY
Turns RNA interference into drugs, mostly for rare and cardiovascular disease.
Full ALNY profile →BioMarin PharmaceuticalBMRN
Rare genetic disorders define the company. It sells enzyme replacement therapies and Voxzogo for dwarfism, and has taken gene therapy into hemophilia.
Full BMRN profile →More ALNY & BMRN comparisons
Other head-to-heads in the Biotech & innovation segment.